Colchicine for cardiovascular therapy: A drug interaction perspective and a safety meta-analysis

秋水仙碱用于心血管治疗:药物相互作用视角和安全性荟萃分析

阅读:1

Abstract

OBJECTIVE: In this study, we aimed to overview the drug interactions between colchicine and cardiovascular drugs and performed a meta-analysis to evaluate the safety profile of colchicine in cardiovascular treatment. METHODS: The drug interactions between colchicine and cardiovascular drugs were evaluated using Medscape-Drug-Interaction-checker. For safety meta-analysis, a systematic literature search was carried out to retrieve eligible studies. Randomized controlled clinical trials that reported a safety analysis and with at least one-year follow-up period were included into the analysis. Meta-analysis was performed using RevMan 5.4 software provided by the Cochrane Collaboration. RESULTS: Serious drug interactions were found between colchicine and lipid-lowering treatments, including all statins and fibrates; carvedilol among the beta-blockers; non-dihydropyridine calcium channel blockers (verapamil and diltiazem); and amiodarone, digoxin, and quinidine. The safety meta-analysis involved 11,594 patients with coronary disease from four trials. The incidences of gastrointestinal adverse events; hematological adverse events; infection; pneumonia; cancer; myalgia; and abnormal nerve sensations were similar between colchicine and control arm. The incidence of cardiovascular death was lower in the colchicine arm; however, the difference did not reach a significant level [relative risk (RR): 0.71, 95% confidence interval (CI) 0.48–1.05; p=0.09]. The incidence of non-cardiovascular death was significantly higher in the colchicine arm (RR: 1.53, 95% CI 1.10–2.14; p=0.01). The rate of all-cause mortality was similar between the two arms (RR: 1.04, 95% CI 0.61–1.78; p=0.88). CONCLUSION: Cardiac patients on colchicine therapy should be carefully monitored to avoid the complications of serious drugs interactions. The reported data in the literature were not sufficient to evaluate the common side effects such as gastrointestinal events and myalgia. The higher incidence of non-cardiovascular death cannot be ignored and should be thoroughly investigated in future studies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。